About usOur teamOur pipelineContact us

Our technology

There is unique potential of Radiopharmaceuticals in treating oncological diseases.
Learn more about our technologies below
Nano-mAbs
Nano-mAbs is the invention of Dr Hong Hoi Ting, an internationally regarded radiopharmaceutical and nuclear medicine expert, formerly from the University of Oxford
  • Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation
  • The product is paired with a diagnostic, using the same antibody vector but labelled with a lower radiation radioisotope for imaging
  • Initial targets are HER-2, TROP-2 and PD-L1

THE NEXT GENERATION STANDARD


HER-2 PRECLINICAL RESULTS

Good binding characteristics, highly specific and no off-target binding


TYPICAL HER-2 IMAGING – FIH RESULTS

99mTc-HER-2 IMAGING IN BREAST CANCER

Uptake of 99mTc-HER-2 was also observed in nodal and distant metastatic lesions in multiple pelvic bones and lungs of a HER2 IHC positive patient with excellent conspicuity to background.  Metastatic disease was confirmed with CT scan.

PD-L1 CLEAR UPTAKE AND ADVANTAGES OF IMAGING Vs BIOPSY

High PD-L1 expression within primary tumour and multiple metastases


Patient: Male, 75 years old, chest x-ray showed lung shadow. CT scan confirmed multiple lesions. Biopsy confirmed squamous cell carcinoma, a lower left lobe lung hilar tumour, 44 x 48 mm is size with multiple metastases, nodal and distant. 99mTc-NM-01 scan results had uptake in primary tumour and multiple metastatic lesions, a strong positive image. PD-L1 IHC likely understated PD-L1 expression for this patient, PD-L1 treatment prognosis for such a patient is expected to be favourable, though further investigation is required.☯


Pivalate
Pivalate is the invention of Professor Eric Aboagye of Imperial College London
  • Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate which utilises the early steps of fatty acid oxidation and is very stable
  • In comparison to the clinical standard in PET imaging, 18F-FDG in prostate and brain cancers, Pivalate showed superior imaging performance and was equally good for two breast cancer models
AVβ6 Integrin
AVβ6 is the invention of internationally regarded integrin expert Professor Johannes Notni, formerly at the Technical University of Munich and now Professor at Essen University
  • AVβ6 is a strong and selective ligand for a cell surface protein called αvβ6-integrin. As such, it can accumulate in tissue areas characterized by high αvβ6-integrin levels
  • There is compelling evidence that αvβ6-Integrin is found in many of the most challenging cancers, such as pancreatic carcinoma, cervical, head-and-neck and certain lung cancers
  • AVβ6 offers an unparalleled performance for radiolabelling with Gallium-68
  • AVβ6 is a highly promising clinical candidate for early detection of the aforementioned conditions by PET imaging
  • Radiopharm Theranositcs plans to design & synthesise a number of conjugates for a therapeutic approach and enter clinical trials at the earliest opportunity
European Journal of Nuclear Medicine and Molecular Imaging – Image of the Month
  • αvβ6-specific peptide
  • PET/CT image of primary tumour in pancreatic head
  • Pancreatic ductal carcinoma confirmed histologically
  • Prominent signals are observed only in kidneys and urinary bladder due to renal excretion
  • No relevant uptake is seen in lungs, stomach, liver and intestines
  • Potential applications for fibrosis, PDAC and other carcinomas (head-and-neck squamous cell, lung adenocarcinoma, colon, cervical, mammary)

Reference:- Quigley, Czech, Sendt, Notni 2021, “PET/CT imaging of pancreatic carcinoma targeting the “cancer integrin αvβ6″,European Journal of Nuclear Medicine and Molecular Imaging

PSA-mAb
PSA-mAb is the invention of Professor David Ulmert formerly of Memorial Sloan Kettering and now UCLA.
  • PSA-mAb is a proprietary humanised monoclonal antibody, capable of targeting free human prostate kallikrein (PSA) in prostate cancer cells and internalising payload
  • The antibody platform enables a radiotheranostic applicable therapy of prostatic cancer through radioimmunotherapy as well as diagnostics of advanced prostate cancer
  • 10 000-fold + higher expression of KLK3 (PSA) in prostate tissue, compared to other tissue
  • [225Ac]-PSA mAb results in curative treatment by sustained tumour regression and a significant increase in median survival time
  • Data demonstrates a stable humanised antibody, without signs of degradation and aggregation

PRECLINICAL RESULTS

Therapy sustained tumor regression and a significant increase in median survival time

While beta-emitting [90Y] PSA-mAb (labelled hu5A10 above) had a more immediate effect on tumour volume, treatment with [225Ac]PSA-mAb resulted in sustained tumour suppression and provided a significant increase in median survival time. The faster response time seen in Yttrium-90 treatment could be attributed to the difference between the chosen radionuclides in half-life and path length. demonstrates a stable humanised antibody, without signs of degradation and aggregation.

DUNP19
DUNP19 is the invention of Professor Ulmert at UCLA.
  • DUNP19 "dual action LRRC15 targeting antibody" is a first-in-class small antibody, that has a unique ability to target both tumour and the surrounding tumour micro-environment ("TME") cells, such as stromal and immune cells which comprise more than 50% of tumour masses.  Currently available antibodies for cancer treatment generally fail to target TME cells.  
  • Applicable to a broad range of currently untreatable cancers.
  • initial indication will be osteosarcoma, a type of bone cancer that primarily targets children, adolescents and young adults.  Osteosarcoma expresses high levels of LRRC15, making it an ideal target for this antibody.
  • In September 2022 the FDA granted Orphan Drug Designation and Pediatric Rare Disease designation to DUNP19 in osteosarcoma.

PRECLINICAL DATA

Humanized Monoclonal Antibody DUNP19
PTPµ
PTPµ (PTPmu) is a peptide molecule biomarker, invented by Dr Susann Brady-Kalnay at Case Western Reserve University in Ohio.
  • A highly specific targeting agent for the detection, imaging and treatment of tumors.
  • When combined with low level radiation, the PTPµ biomarker functions as a highly specific PET imaging agent.
  • When combined with high energy radiation, the PTPµ biomarker works as a radiopharmaceutical theranostic to destroy tumours.
  • In therapeutic mode, the biomarker labels tumor cells far away from the main tumor mass, achieving specific recognition of the full extent of an invasive tumor.
  • The biomarker recognises PTPµ in multiple tumor types including brain and gynaecological tumors.
  • Initial indication will focus on glioblastoma.

PRECLINICAL DATA

PTPy-targeted agent detects tumor cells but not normal cells

Sign up to our mailing list.

Receive all the latest news from Radiopharm Theranostics.